O	0	1	[
O	1	11	Prevention
O	12	15	and
O	16	25	treatment
O	26	28	of
B-condition	29	38	aromatase
I-condition	39	48	inhibitor
I-condition	48	49	-
I-condition	49	59	associated
I-condition	60	64	bone
I-condition	65	69	loss
O	70	72	by
B-intervention	73	79	shugan
I-intervention	80	86	jiangu
I-intervention	87	93	recipe
O	94	96	in
O	97	111	postmenopausal
O	112	117	women
O	118	122	with
O	123	129	breast
O	130	136	cancer
O	136	137	:
O	138	139	a
O	140	148	clinical
O	149	154	study
O	154	155	]
O	155	156	.

O	157	159	To
O	160	165	study
O	166	169	the
O	170	176	effect
O	177	179	of
O	180	186	Shugan
O	187	193	Jiangu
O	194	200	Recipe
O	201	202	(
O	202	205	SJR
O	205	206	)
O	207	209	on
O	210	214	bone
O	215	222	mineral
O	223	230	density
O	231	232	(
O	232	235	BMD
O	235	236	)
O	237	240	and
O	241	246	serum
O	247	251	bone
O	252	261	metabolic
O	262	273	biochemical
O	274	281	markers
O	282	284	in
O	285	299	postmenopausal
O	300	306	breast
O	307	313	cancer
O	314	322	patients
O	323	327	with
O	328	338	osteopenia
O	338	339	.

O	340	347	Totally
B-total-participants	348	350	38
B-eligibility	351	359	patients
I-eligibility	360	362	of
I-eligibility	363	377	postmenopausal
I-eligibility	378	383	women
I-eligibility	384	388	with
I-eligibility	389	395	breast
I-eligibility	396	402	cancer
I-eligibility	402	403	,
I-eligibility	404	407	who
I-eligibility	408	416	received
I-eligibility	417	426	aromatase
I-eligibility	427	437	inhibitors
I-eligibility	438	439	(
I-eligibility	439	442	AIs
I-eligibility	442	443	)
O	443	444	,
O	445	449	were
O	450	458	assigned
O	459	461	to
O	462	465	the
O	466	475	treatment
O	476	481	group
O	482	483	(
B-intervention-participants	483	485	21
O	486	491	cases
O	491	492	)
O	493	496	and
O	497	500	the
B-control	501	508	control
I-control	509	514	group
O	515	516	(
B-control-participants	516	518	17
O	519	524	cases
O	524	525	)
O	526	528	by
O	529	534	using
O	535	541	random
O	542	547	digit
O	548	553	table
O	553	554	.

O	555	558	All
O	559	567	patients
O	568	572	took
O	573	581	Caltrate
O	582	583	D
O	584	590	Tablet
O	591	592	(
O	592	602	containing
O	603	605	Ca
O	606	609	600
O	610	612	mg
O	613	616	and
O	617	620	Vit
O	621	623	D3
O	624	627	125
O	628	630	IU
O	630	631	)
O	631	632	,
O	633	636	one
O	637	643	tablet
O	644	649	daily
O	649	650	.

O	651	659	Patients
O	660	662	in
O	663	666	the
O	667	676	treatment
O	677	682	group
O	683	687	took
O	688	691	SJR
O	691	692	,
O	693	694	6
O	695	696	g
O	697	701	each
O	702	706	time
O	706	707	,
O	708	713	twice
O	714	719	daily
O	720	723	for
O	724	725	6
O	726	736	successive
O	737	743	months
O	743	744	.

O	745	748	The
O	749	753	bone
O	754	761	mineral
O	762	769	density
O	770	771	(
O	771	774	BMD
O	774	775	)
O	776	781	level
O	782	785	was
O	786	794	detected
O	795	801	before
O	802	811	treatment
O	812	815	and
O	816	818	at
O	819	825	months
O	826	827	6
O	828	833	after
O	834	843	treatment
O	843	844	.

O	845	851	Levels
O	852	854	of
O	855	859	bone
O	860	868	alkaline
O	869	880	phosphatase
O	881	882	(
O	882	886	BALP
O	886	887	)
O	887	888	,
O	889	893	bone
O	894	897	gla
O	898	905	protein
O	906	907	(
O	907	910	BGP
O	910	911	)
O	911	912	,
O	913	921	tartrate
O	921	922	-
O	922	931	resistant
O	932	936	acid
O	937	948	phosphatase
O	949	950	(
O	950	954	TRAP
O	954	955	)
O	955	956	,
O	957	960	and
O	961	962	C
O	962	963	-
O	963	971	terminal
O	972	983	telopeptide
O	984	986	of
O	987	991	type
O	992	994	II
O	995	1003	collagen
O	1004	1005	(
O	1005	1008	CTX
O	1008	1009	-
O	1009	1011	II
O	1011	1012	)
O	1013	1017	were
O	1018	1026	detected
O	1027	1029	by
O	1030	1036	enzyme
O	1037	1043	linked
O	1044	1057	immunosorbent
O	1058	1063	assay
O	1064	1065	(
O	1065	1070	ELISA
O	1070	1071	)
O	1071	1072	.

O	1073	1076	The
O	1077	1081	drug
O	1082	1088	safety
O	1089	1092	was
O	1093	1097	also
O	1098	1106	assessed
O	1106	1107	.

O	1108	1116	Compared
O	1117	1121	with
O	1122	1128	before
O	1129	1138	treatment
O	1138	1139	,
B-outcome	1140	1143	BMD
I-outcome	1144	1146	of
I-outcome	1147	1149	L2
I-outcome	1149	1150	-
I-outcome	1150	1151	4
I-outcome	1152	1155	and
I-outcome	1156	1161	femur
I-outcome	1162	1166	neck
O	1167	1176	obviously
O	1177	1186	increased
O	1187	1189	in
O	1190	1193	the
O	1194	1203	treatment
O	1204	1209	group
O	1210	1212	at
O	1213	1218	month
O	1219	1220	6
O	1221	1226	after
O	1227	1236	treatment
O	1237	1238	(
O	1238	1239	P
O	1240	1241	<
O	1242	1243	0
O	1243	1244	.
O	1244	1246	01
O	1246	1247	)
O	1247	1248	,
B-outcome	1249	1254	serum
I-outcome	1255	1259	BALP
I-outcome	1260	1263	and
I-outcome	1264	1268	TRAP
O	1269	1278	decreased
O	1279	1280	(
O	1280	1281	P
O	1282	1283	<
O	1284	1285	0
O	1285	1286	.
O	1286	1288	05
O	1288	1289	)
O	1289	1290	.

O	1291	1299	Compared
O	1300	1304	with
O	1305	1311	before
O	1312	1321	treatment
O	1321	1322	,
B-outcome	1323	1326	BMD
I-outcome	1327	1329	of
I-outcome	1330	1332	L2
I-outcome	1332	1333	-
I-outcome	1333	1334	4
I-outcome	1335	1338	and
I-outcome	1339	1344	femur
I-outcome	1345	1349	neck
O	1350	1359	obviously
O	1360	1369	decreased
O	1370	1372	in
O	1373	1376	the
O	1377	1384	control
O	1385	1390	group
O	1391	1393	at
O	1394	1399	month
O	1400	1401	6
O	1402	1407	after
O	1408	1417	treatment
O	1418	1419	(
O	1419	1420	P
O	1421	1422	<
O	1423	1424	0
O	1424	1425	.
O	1425	1427	05
O	1427	1428	)
O	1428	1429	,
B-outcome	1430	1435	serum
I-outcome	1436	1440	BALP
I-outcome	1441	1444	and
I-outcome	1445	1449	TRAP
O	1450	1459	increased
O	1460	1461	(
O	1461	1462	P
O	1463	1464	<
O	1465	1466	0
O	1466	1467	.
O	1467	1469	01
O	1469	1470	)
O	1470	1471	.

O	1472	1480	Compared
O	1481	1485	with
O	1486	1489	the
O	1490	1497	control
O	1498	1503	group
O	1503	1504	,
B-outcome	1505	1511	lumbar
I-outcome	1512	1515	and
I-outcome	1516	1521	femur
I-outcome	1522	1526	neck
I-outcome	1527	1530	BMD
O	1531	1540	obviously
O	1541	1550	increased
O	1550	1551	,
B-outcome	1552	1557	serum
I-outcome	1558	1564	levels
I-outcome	1565	1567	of
I-outcome	1568	1571	BGP
I-outcome	1572	1575	and
I-outcome	1576	1580	BALP
O	1581	1590	obviously
O	1591	1600	decreased
O	1600	1601	,
O	1602	1605	and
B-outcome	1606	1611	serum
I-outcome	1612	1618	levels
I-outcome	1619	1621	of
I-outcome	1622	1625	CTX
I-outcome	1625	1626	-
I-outcome	1626	1628	II
I-outcome	1629	1632	and
I-outcome	1633	1637	TRAP
O	1638	1647	obviously
O	1648	1657	increased
O	1658	1660	in
O	1661	1664	the
O	1665	1674	treatment
O	1675	1680	group
O	1681	1683	at
O	1684	1689	month
O	1690	1691	6
O	1692	1697	after
O	1698	1707	treatment
O	1708	1709	(
O	1709	1710	P
O	1711	1712	<
O	1713	1714	0
O	1714	1715	.
O	1715	1717	01
O	1717	1718	)
O	1718	1719	.

B-outcome	1720	1722	No
I-outcome	1723	1730	serious
I-outcome	1731	1738	adverse
I-outcome	1739	1744	event
O	1745	1753	occurred
O	1754	1760	during
O	1761	1764	the
O	1765	1774	treatment
O	1775	1781	period
O	1781	1782	.

B-outcome	1783	1787	Bone
I-outcome	1788	1796	fracture
O	1797	1805	occurred
O	1806	1808	in
B-cv-bin-abs	1809	1812	one
O	1813	1817	case
O	1818	1820	of
O	1821	1824	the
O	1825	1832	control
O	1833	1838	group
O	1839	1840	(
B-cv-bin-percent	1840	1841	5
I-cv-bin-percent	1841	1842	.
I-cv-bin-percent	1842	1843	8
I-cv-bin-percent	1843	1844	%
O	1844	1845	)
O	1845	1846	.

O	1847	1850	SJR
O	1851	1856	could
O	1857	1866	attenuate
O	1867	1871	bone
O	1872	1876	loss
O	1877	1879	of
O	1880	1894	postmenopausal
O	1895	1900	women
O	1901	1905	with
O	1906	1912	breast
O	1913	1919	cancer
O	1920	1923	who
O	1924	1932	received
O	1933	1936	AIs
O	1936	1937	,
O	1938	1946	increase
O	1947	1950	BMD
O	1951	1954	and
O	1955	1962	improve
O	1963	1971	abnormal
O	1972	1976	bone
O	1977	1987	metabolism
O	1987	1988	.
